China Biotechnology Market Size & Outlook, 2023-2030
China biotechnology market, 2018-2030 (US$M)
Related Markets
China biotechnology market highlights
- The China biotechnology market generated a revenue of USD 74,157.0 million in 2023 and is expected to reach USD 262,958.1 million by 2030.
- The China market is expected to grow at a CAGR of 19.8% from 2024 to 2030.
- In terms of segment, health was the largest revenue generating application in 2023.
- Bioinformatics is the most lucrative application segment registering the fastest growth during the forecast period.
Biotechnology market data book summary
| Market revenue in 2023 | USD 74,157.0 million |
| Market revenue in 2030 | USD 262,958.1 million |
| Growth rate | 19.8% (CAGR from 2023 to 2030) |
| Largest segment | Health |
| Fastest growing segment | Bioinformatics |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Health, Food & Agriculture, Natural reseources & Environment, Industrial Processing, Bioinformatics, Others Applications |
| Key market players worldwide | AstraZeneca PLC, Gilead Sciences Inc, Bristol-Myers Squibb Co, Sanofi SA, Biogen Inc, Abbott Laboratories, Pfizer Inc, Amgen Inc, Novo Nordisk A/S ADR, Merck KGaA, Johnson & Johnson, Novartis AG ADR, Roche Holding AG, Lonza Group Ltd |
Other key industry trends
- In terms of revenue, China accounted for 4.8% of the global biotechnology market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan biotechnology market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 262,958.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biotechnology Market Scope
Biotechnology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China biotechnology market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biotechnology market will help companies and investors design strategic landscapes.
Health was the largest segment with a revenue share of 45.06% in 2023. Horizon Databook has segmented the China biotechnology market based on health, food & agriculture, natural reseources & environment, industrial processing, bioinformatics, others applications covering the revenue growth of each sub-segment from 2018 to 2030.
China is estimated to be the second largest country for T-cell therapy clinical trials globally. Approximately 80% of these trials are conducted by local hospitals, indicating increase in cancer research. Thus, market players are focusing on cancer immunotherapy-based products in China.
Some of the major companies in the market are Innovative Cellular Therapeutics, Cellular Biomedicine Group, CARs gen Therapeutics, Person Gen Biomedicine, and Hebei Sen lang Biotech. Thus, rising research in the country is expected to fuel the market growth during the forecast period.
In China, lab automation is not widely accepted, but the market is picking up pace with growing demand for rapid and high-throughput testing. The head of a clinical laboratory at Zhong shan Hospital and Peking Union Medical College Hospital stated that the demand for better healthcare services has increased significantly in the country.
Reasons to subscribe to China biotechnology market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China biotechnology market databook
-
Our clientele includes a mix of biotechnology market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China biotechnology market , including forecasts for subscribers. This country databook contains high-level insights into China biotechnology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China biotechnology market size, by application, 2018-2030 (US$M)
China Biotechnology Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
